Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the most frequent pancreatic cancer type and is characterized by a dismal prognosis due to late diagnosis, local tumor invasion, frequent distant metastases and poor sensitivity to current therapy. In this context, circulating tumor cells and circulating tumor DNA constitute easily accessible blood‐borne tumor biomarkers that may prove their clinical interest for screening, early diagnosis and metastatic risk assessment of PDAC. Moreover these markers represent a tool to assess PDAC mutational landscape. In this review, together with key biological findings, we summarize the clinical results obtained using “liquid biopsies” at the different stages of the disease, for early and metastatic diagnosis as well as monitoring during therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · cited 1×
“Patients with metastatic PDAC have a very limited life expectancy, despite some incremental progresses obtained with FOLFIRINOX and the gemcitabine nabepaclitaxel combination (Conroy et al., 2011; Von Hoff et al., 2013).”
BackgroundIncreased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542 · cited 1×
“Detection rates ranged from 10% to 80%, depending on the technique and disease stage (Allard et al., 2004; Bidard et al., 2013; Kurihara et al., 2008; Mataki et al., 2004).”
BackgroundLiquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058
Labelle, M., Begum, S., & Hynes, R. O. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.009 · Cited by 1,833
Iacobuzio-Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C. M., Vilardell, F., Wang, Z., Keller, J. W., Banerjee, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7188 · Cited by 1,081 · cited 1×
“(Iacobuzio-Donahue et al., 2009).”
Croce, C. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072367 · Cited by 1,055
Circulating nucleic acids (CNAs) and cancer—A survey
Fleischhacker, M., & Schmidt, B. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.10.001 · Cited by 851
Cited by
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
McGuigan, A., Kelly, P., Turkington, R. C., Jones, C., Coleman, H. G., & McCain, R. S. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i43.4846 · Cited by 1,908
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Cancer Diagnosis: From Tumor to Liquid Biopsy and Beyond
Vaidyanathan, R., Soon, R. H., Zhang, P., Jiang, K., & Lim, C. T. (2018) · Lab on a Chip · doi:10.1039/c8lc00684a · Cited by 259
Liquid biopsy for cancer: review and implications for the radiologist
Underwood, J. J., Quadri, R. S., Kalva, S. P., Shah, H., Sanjeeviah, A. R., Beg, M. S., & Sutphin, P. D. (2020) · Radiology · doi:10.1148/radiol.2019182584 · Cited by 87
Metadata
- Authors
- Riva, F., Dronov, O. I., Khomenko, D. I., Huguet, F., Louvet, C., Mariani, P., Stern, M.-H., Lantz, O., Proudhon, C., Pierga, J.-Y., & Bidard, F.-C.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2016-01-22
- Volume
- 10
- Issue
- 3
- Pages
- 481-493
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2251681152
- Cited by
- 93
- References
- 17
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. https://app.cochat.ai/papers/10.1016/j.molonc.2016.01.006
- The paper
- Riva, F., Dronov, O. I., Khomenko, D. I., Huguet, F., Louvet, C., Mariani, P., Stern, M.-H., Lantz, O., Proudhon, C., Pierga, J.-Y., & Bidard, F.-C. (2016). Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. Molecular Oncology. https://doi.org/10.1016/j.molonc.2016.01.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.